10 hypersensitivity appu
TRANSCRIPT
![Page 1: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/1.jpg)
HYPERSENSITIVITY AND EVALUATION
METHODS
APARNA.SM.PHARMACYG.PULLA REDDY COLLEGE OF PHARMACY
![Page 2: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/2.jpg)
2
HYPERSENSITIVITY Hypersensitivity reaction resulting from
specific interactions between antigens (allergens) and either antibodies or sensitized lymphocytes.
Hypersensitivity reaction resulting from specific interactions between antigens (allergens) and either antibodies or sensitized lymphocytes
Diffuse urticaria Anaphylactic response to bee sting
![Page 3: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/3.jpg)
![Page 4: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/4.jpg)
TYPE –IMast cell degranulation mediated by antigen cross-linking of IgE bound to IgE Fc receptors (FcRI).
![Page 5: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/5.jpg)
Mediators released during activation of mast cells.
![Page 6: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/6.jpg)
MECHANISM IN TYPE-I
![Page 7: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/7.jpg)
(A)Electron micrograph of normal mast cell illustrating large monocyte-like nucleus and electron-dense granules.
(B) (B) Mast cell that has been triggered and is beginning to release contents of granules, as seen by their decrease in opacity and formation of vacuoles connecting with exterior.
ELECTRON MICROSCOPIC VIEW
![Page 8: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/8.jpg)
Clinical Examples
Hay fever and Asthma----To pollen, house dust, pets etc.
Urticaria(Hives)---Drugs,food. Reddening and itching of skin.
Systemic anaphylaxis---Inj. of Penicillin,Insect bites.
![Page 9: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/9.jpg)
Type II IgE-mediated
![Page 10: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/10.jpg)
THREE TYPES OF MECHANISMS IN TYPE- II HYP
![Page 11: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/11.jpg)
Drug-Induced Reactions:Adherence to Blood
Components
complementcomplement
blood cell adsorbed drug blood cell adsorbed drug or antigen drug metaboliteor antigen drug metabolite
antibody to drugantibody to drug
lysis
![Page 12: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/12.jpg)
DISEASES OF TYPE-II
Autoimmune hemolytic anemia Thrombocytopenia Erythroblastosis fetalis Goodpasture's syndrome
![Page 13: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/13.jpg)
![Page 14: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/14.jpg)
Hemolytic Disease of the New Born
RhD-ve mother
RhD +ve fetus
Anti-RhD Abs
RhD +ve fetus
![Page 15: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/15.jpg)
‘A’ blood group mother
‘B’ blood group fetus
Anti-B Abs
If mother and fetus have different blood groups, hemolytic disease does not occur.
![Page 16: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/16.jpg)
Prophylaxis (RhoGAM)
RhD-ve mother
RhD +ve fetus
Anti-RhD Abs
RhD +ve fetusMid-term injection of RhoGAM and a second injection within a few days of delivery
![Page 17: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/17.jpg)
Immune Complex Mediated Hypersensitivity-III
![Page 18: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/18.jpg)
Type III hypersensitivity mechanism
![Page 19: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/19.jpg)
Type III hypersensitivity mechanism
![Page 20: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/20.jpg)
Examples of Type-III
Serum sickness Arthus reaction Systemic lupus erythematosus (SLE) Glomerulonephrites
![Page 21: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/21.jpg)
Serum sickness
Systemic lupus erythematosus
![Page 22: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/22.jpg)
DELAYED TYPE -IV
![Page 23: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/23.jpg)
TYPE IV OR DTH– REACTION TO POISON IVY
![Page 24: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/24.jpg)
Examples of Type IV
Contact dermatitis Tuberculin skin test Chronic transplant rejection Multiple sclerosis
![Page 25: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/25.jpg)
Contact Dermatitis
ECZEMA
ALLERGIC SKIN REACTIONS
![Page 26: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/26.jpg)
Leprosy
Hyporesponse
Normal response
Hyper response
Fluid filled blebs with bacteria
small skin lesion
Severetissue damage
![Page 27: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/27.jpg)
Type V Hypersensitivity / Auto immune
This is an additional type that is sometimes used as a distinction from Type 2
Instead of binding to cell surface components, the
antibodies recognize and bind to the cell surface receptors , which either prevents the intended ligand binding with the receptor or mimics the effects of the ligand, thus impairing cell signaling
![Page 28: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/28.jpg)
Examples of Type V Grave's disease Myasthenia Gravis Hashimoto's thyroiditis Systemic lupus erythematosus
![Page 29: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/29.jpg)
OECD TEST GUIDE LINESOECD TEST GUIDE LINES
![Page 30: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/30.jpg)
EVALUATION OF HYP :QUALITATIVE
![Page 31: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/31.jpg)
![Page 32: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/32.jpg)
LYMPH NODE:QUANTITATIVE ASSAY
* The basic principle is to induce proliferation of lymphocytes in the lymph nodes draining the site of test substance application.
* This proliferation is proportional to the dose and to the potency of the applied allergen and provides a simple means of obtaining a quantitative measurement of sensitization.
* Proliferation is measured by comparing the mean proliferation in
each test group to the vehicle treated control (VC) group.
* The ratio of the mean proliferation in each treated group to that in the VC group, termed the SI, is determined, and should be ≥1.8.
![Page 33: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/33.jpg)
* The methods described here are based on the use of measuring ATP content by bioluminescence to indicate an increased number of proliferating cells in the draining auricular lymph nodes
* The bioluminescent method utilises the luciferase enzyme to catalyse the formation of light from ATP and luciferin according to the following reaction:
ATP+LUCIFERIN+OXYGEN luciferase
OXYLUCIFERIN+AMP+Ppi+CO2+LIGHT
* The emitted light intensity is linearly related to the ATP concentration and is measured using a luminometer* The luciferin-luciferase assay is a sensitive method for ATP quantitation used in a wide variety of applications.
![Page 34: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/34.jpg)
IN-VITRO SCREENING METHODS
![Page 35: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/35.jpg)
REFERENCES Willey drug safety evaluation (2002)by shayne c.Gad OECD (2010), Skin Sensitization: Local Lymph Node Assay,
Test Guideline No. 429, Guidelines for the Testing of Chemicals, OECD, Paris. Available at: [http://www.oecd.org/env/testguidelines]
http://iccvam.niehs.nih.gov/docs/immunotox_docs/llna/llnarep.pdf]
OECD (1992), Skin Sensitisation, Test Guideline No. 406, Guidelines for Testing of Chemicals, OECD, Paris. Available at: [http://www.oecd.org/env/testguidelines]
OECD (2002), Acute Dermal Irritation/Corrosion, Test Guideline No. 404, Guidelines for Testing of Chemicals, OECD, Paris. Available at: [http://www.oecd.org/env/testguidelines]
![Page 36: 10 hypersensitivity appu](https://reader036.vdocuments.us/reader036/viewer/2022062311/58ed25251a28abf63c8b46bd/html5/thumbnails/36.jpg)